<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414516</url>
  </required_header>
  <id_info>
    <org_study_id>OBP-801-001</org_study_id>
    <nct_id>NCT02414516</nct_id>
  </id_info>
  <brief_title>A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1a Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncolys BioPharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncolys BioPharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1a, single center, open-label, repeat dose study will evaluate the safety,
      efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid
      tumors.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile; AUC, Cmax, and t1/2</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR)</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of Objective Response (DOR)</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>OBP-801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBP-801</intervention_name>
    <description>OBP-801 will be administered IV</description>
    <arm_group_label>OBP-801</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria

        Patients must meet all of the following inclusion criteria to be eligible for enrollment
        into the study:

          -  Histologically or cytologically confirmed metastatic or unresectable solid tumor.

          -  Has failed treatment with all standard therapies for their malignancy.

          -  Adequate Karnofsky Performance Status.

          -  An expected survival of at least 3 months.

          -  Adequate organ and bone marrow function.

          -  Signed informed consent form for study participation prior to screening.

        Patient Exclusion Criteria

        Patients presenting with any of the following will be excluded in the study:

          -  Clinically significant disease as defined by the protocol.

          -  Surgical therapy or other therapies within period as defined by the protocol.

          -  Any condition that will interfere with compliance with the protocol as determined by
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Makoto Seki, Ph.D.</last_name>
    <phone>81-3-5472-1578</phone>
    <email>seki@oncolys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>800-527-6266</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDAC</keyword>
  <keyword>Epigenetic</keyword>
  <keyword>Histone</keyword>
  <keyword>Acetylation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

